COVID-19 vaccine acceptance among pregnant women worldwide: A systematic review and meta-analysis

Milad Azami,⁎, Marzieh Parizad Nasirkandy, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar

1 Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran, 2 Department of Obstetrics and Gynecology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, 3 Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran, 4 Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁎ ranjbarre@gmail.com

Abstract

Background

The COVID-19 pandemic has led to the death of many people worldwide. The World Health Organization (WHO) has declared vaccine resistance as one of the greatest health threats in the world even before the COVID-19 epidemic. The aim of this study was to evaluate the acceptance of COVID-19 vaccine in pregnant women.

Method

We performed this systematic review and meta-analysis in accordance with the PRISMA guidelines. We applied the standard search strategy to the PubMed/Medline, Web of Science (ISI), Scopus, Science Direct, Cochrane Library, EMBASE, and EBSCO databases, and the Google Scholar search engine. Heterogeneity between studies was relatively high and therefore meta-analyses were performed based on random effects model with 95% CI using STATA version 16.

Results

In 16 articles with a sample size of 19219 pregnant women, the acceptance of COVID-19 vaccine was estimated 53.46% (95%CI: 47.64%-59.24%). Subgroup analysis was performed based on continent (p = 0.796), data collection method (p = 0.450) and meta-regression based on the month of the study (P<0.001), and only meta-regression was significant based on the month of the study. The effect of some variables such as gravid (OR = 1.02 [95%CI: 0.90–1.16]), maternal age was (OR = 1.02 [95%CI: 0.93–1.11]) and history of influenza vaccination (OR = 0.87 [95%CI: 0.71–1.06]) on COVID-19 vaccine acceptance was evaluated, which was not significant.

Conclusion

The prevalence of COVID-19 vaccine acceptance in pregnant women was 53.46%, which was much lower than the general COVID-19 vaccination. Therefore, necessary
interventions should be taken to increase the acceptance of the vaccine, address safety concerns and educate about it.

1. Introduction

The coronavirus disease of 2019 (COVID-19) pandemic has led to the death of many people worldwide [1]. High rate of human mortality has created public health challenges, disrupted the supply chain and the economy, and on the other hand has created a comprehensive mental health crisis [2, 3].

Pregnant women and postpartum women are more likely to get infected with COVID-19 and get excessively stressed out about this disease compared to their non-pregnant peers [4]. Research on pregnant women has shown that although the symptoms of the disease and the death rate are similar to those of non-pregnant women, these individuals are at greater risk for severe disease, intensive care admission, and invasive ventilation [5, 6].

COVID-19 in mothers can cause preterm delivery, stillbirth, multiple organ dysfunction syndrome, increased heart rate and fetal distress, premature rupture of membranes, increased cesarean section rate and death [1, 7]. It is also worth noting that COVID-19 pandemic causes fears for the health of the fetus and its health among pregnant women, which significantly affects their well-being [8].

To date, many pregnant women in the United States, Europe, and some Asian countries have been vaccinated against COVID-19 by different vaccines. With the development of vaccines and the global start of vaccination, there is hope for saving more lives and reducing the severe effects of the disease in all population groups. However, due to the emergency use of these vaccines and also lack of clinical information about their effects on pregnancy and fetus, there are ambiguities in this regard [9, 10].

According to a study by Pratama et al. in a review of vaccine safety during pregnancy, Pfizer-BioNTech and Moderna vaccines are effective in preventing infection and are safe for pregnancy and the fetus [11]. These vaccines are made from modified version of a different virus (adenovirus). Previously, similar vaccines using the same viral vector have been tested in all trimesters of pregnancy and have shown no adverse effects on the infant [12]. In another study, evidence of the safety and efficacy of Pfizer BNT162b2 in pregnancy was presented, which showed health benefits for both mother and infant [13].

It is necessary to know the factors affecting vaccine acceptance among different social groups, including pregnant women [14]. Pregnant women often play a key role in getting their children vaccinated. However, the results obtained by studies about COVID-19 vaccine acceptance among pregnant women show contradictory results [1, 15, 16]. The World Health Organization (WHO) has declared vaccine resistance as one of the greatest health threats in the world even before the COVID-19 epidemic [17]. Preliminary research on COVID-19 vaccine acceptance predicts unprecedented challenges for global vaccination [18]. On the other hand, the National Advisory Committee on Immunization (NACI) and the American College of Obstetricians and Gynecologists (ACOG) recommend that pregnant women must be vaccinated. Therefore, the confusion of pregnant women in deciding on the COVID-19 vaccine has hampered its acceptance. So far, various studies have examined vaccine acceptance in the world, which have led to different results [19].

Considering that obtaining an overall estimate can pave the way for health policymakers to accurately estimate the prevalence of COVID-19 vaccine acceptance in pregnant women [20],
we conducted a systematic review and meta-analysis to combine the findings from existing studies in this area and provide a clearer picture of its prevalence in the world [21].

2. Method

2.1. Study protocol

Before beginning this study, in the assessment of protocol registry for systematic reviews, it was found that the review protocol was not recorded in any database. We performed this systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [22]. Each of the research stages, including search, selection of articles, data extraction, and qualitative evaluation of selected studies, was performed independently by at least two authors (M.A, R.R, and M.P) and the contradictions were resolved by consensus.

2.2. Search strategy

We did our initial literature search in October 2021. We applied the standard search strategy to the PubMed/Medline, Web of Science (ISI), Scopus, Science Direct, Cochrane Library, EMBASE, and EBSCO databases, and the Google Scholar search engine. We reviewed reference lists of identified articles to find other related articles. Searches were last updated in November 2021.

The search was performed using the following Mesh terms: “Coronavirus”[Mesh], “COVID-19”[Mesh], “SARS-CoV-2”[Mesh], “COVID-19 Vaccines”[Mesh], “Pregnancy”[Mesh], and “Pregnant Women” [Mesh]. An example of a combined search in PubMed is as follows: (“Coronavirus”[Mesh]) OR (“COVID-19”[Mesh] OR “SARS-CoV-2”[Mesh] OR “COVID-19 Vaccines”[Mesh])) AND (“Pregnancy”[Mesh] OR “Pregnant Women”[Mesh]).

2.3. Inclusion and exclusion criteria

The included articles had the following inclusion criteria: English articles based on a cross-sectional design with short abstract that examined vaccine acceptance in pregnant women. Articles were excluded if: 1) they used a selective sampling (e.g., interventional trials after group allocation), 2) their samples included groups other than pregnant women, 3) they had sample size of \(\leq 50\), 4) their subject was not related to our target subject, 5) they were duplicate studies, 6) they were case reports, review articles, congress, letters to the editor without quantitative data, and dissertations, 7) they had low quality in qualitative evaluation, and 8) they did not separate pregnant women from lactating women.

2.4. Article selection

Titles and abstracts of all identified reports were reviewed. The full text of the articles was then evaluated based on inclusion and exclusion criteria.

2.5. Data extraction

The following data were extracted from each article: First author, year of publication, month of study, study design, number of participants (total, based on pregnancy trimester, based on group, based on history of influenza vaccine injection, based on age [below and above 35 years]), Data collection tools, acceptance of COVID-19 vaccine (total, based on pregnancy trimester, based on history of influenza vaccine injection, based on age) and odds ratio (OR) and 95% confidence interval (CI) for variables.
2.6. Quality assessment
The adapted version of Newcastle-Ottawa Scale was used to assess the quality of nonrandomized studies [23]. The maximum attainable score was 9. Three categories were defined for the quality of articles: low quality (score less than 5), medium quality (score 6–7) and high score (score 8–9).

2.7. Statistical analysis
Heterogeneity between studies was relatively high and therefore meta-analyses were performed based on random effects model with 95% CI using STATA version 13. Heterogeneity was assessed using $I^2$ with thresholds $\geq 25\%$, $\geq 50\%$ and $\geq 75\%$, indicating low, medium and high heterogeneity, respectively [24]. We used the OR$_s$ index and 95% CI to show the effect of variables such as age, history of influenza vaccine and gravid on COVID-19 vaccine acceptance. Finally, we reported the results as OR and 95% CI. In studies that did not report OR$_s$ index and 95% CI, we obtained case and control cases based on the total sample size of each group as well as the rate of COVID-19 vaccine acceptance in each group. Sensitivity analysis examined whether prevalence estimates were influenced by study design. Publication bias was assessed using Begg’s and Egger’s tests [25, 26]. P-value less than 0.05 were considered statistically significant.

3. Results
3.1. Search results and features of articles
In the initial search, 2,324 articles on vaccine acceptance in the world were found. After reviewing the title and abstract, 29 articles were identified as relevant and after reviewing the full text, 13 articles were omitted due to lack of necessary criteria and finally 16 articles were entered into qualitative synthesis and among them, 16 eligible articles (related to acceptance of vaccine in pregnant women) entered the meta-analysis stage (Fig 1). Table 1 shows the specifications of each study.

3.2. Acceptance of COVID-19 vaccine and sensitivity analysis
In 16 articles with a sample size of 19219 pregnant women, the acceptance of COVID-19 vaccine was estimated at 53.46% (95% CI: 47.64–59.24) (Fig 2A). Furthermore, the sensitivity analysis with the omission of one study at a time showed that the results are still robust and the omission of one study does not affect the overall results (Fig 2B).

3.3. Subgroup analysis based on continent
COVID-19 vaccine acceptance among pregnant women in Europe, Asia, Africa, and the United States were respectively estimated as 53.31% (95% CI: 46.05–60.49), 56.66% (95% CI: 33.64–78.26), 55.00% (95% CI: 30.76–78.04), and 50.36% (95% CI: 47.64–59.24) and heterogeneity between subgroups was not significant (p = 0.796) (Fig 3A).

3.4. Subgroup analysis based on data collection method
COVID-19 vaccine acceptance among pregnant women was estimated at 56.16% (95% CI: 42.95–68.93) in face-to-face visit and 50.78% (95% CI: 46.35–55.21) in online visit. Heterogeneity was not significant between subgroups (p = 0.450) (Fig 3B).
3.5. Effect of maternal age on COVID-19 vaccine acceptance

COVID-19 vaccine acceptance among pregnant women fewer than 35 and over 35 years was 55.93% (95% CI: 42.92–68.53) and 57.61% (95% CI: 48.42–66.56), respectively (Fig 4A and 4B). Furthermore, the relationship between COVID-19 vaccine acceptance for pregnant women and their age (fewer than 35 to over 35 years) was (OR = 1.02 [95% CI: 0.93–1.11]; Heterogeneity: $I^2 = 0$, $P = 0.798$), which indicates that the relationship between vaccine acceptance in pregnant women and the age of pregnant women is not significant (Fig 4C).
3.6. The effect of gravid on COVID-19 vaccine acceptance

COVID-19 vaccine acceptance was 68.11% (95% CI: 55.13–79.82) among primigravida pregnant women and 70.98% (95% CI: 60.32–80.59) in multigravida women (Fig 5A and 5B). Moreover, the relationship between receiving COVID-19 vaccine in pregnant women and gravid was (OR = 1.02 [95% CI: 0.90–1.16]; Heterogeneity: $I^2 = 0, P = 0.834$), which indicates that the relationship between vaccine acceptance in pregnant women and gravid in them is not significant (Fig 5C).

3.7. The effect of influenza vaccination history on COVID-19 vaccine acceptance

The prevalence of COVID-19 vaccine acceptance among pregnant women with a history of influenza vaccination was 61.13% (95% CI: 57.24–64.95) and without a history of influenza

Table 1. Summary of characteristics in studies into a meta-analysis.

| Ref. | First author, Published Year | Study duration | Place | Method to collection data | Design | Quality |
|------|-----------------------------|----------------|-------|---------------------------|--------|---------|
| [27] | Goncu Ayhan S, 2021         | January, 2021  | Ankara, Turkey | During visit | Cross-sectional | All 300, Accepted 111 | Medium risk |
| [28] | Sutton D, 2021              | January, 2021  | New York     | Online survey    | Cross-sectional | All 216, Accepted 86  | Medium risk |
| [29] | Jayagobi A, 2021            | March to May 2021 | Singapore | Online survey    | Cross-sectional | All 201, Accepted 61  | Medium risk |
| [30] | Mose A, 2021                | January 2021   | Ethiopia     | During visit     | Cross-sectional | All 396, Accepted 280 | Medium risk |
| [31] | Skirrow H, 2021             | August to October 2020 | UK | Online survey    | Cross-sectional | All 1181, Accepted 732 | Medium risk |
| [32] | Skjefte M, 2021             | October to November 2020 | United States (US), India, Brazil, Russia, Spain, Argentina, Colombia, UK, Mexico, Peru, South Africa, Italy, Chile and the Philippines, Australia and New Zealand | Online survey    | Cross-sectional | All 5282, Accepted 2747 | Low risk |
| [33] | Levy A T, 2021              | 14th December to 14th January 2020 | New York | During visit | Cross-sectional | All 653, Accepted 381 | Medium risk |
| [34] | Tao L, 2021                 | 13th November to 27th November 2020 | China | During visit | Cross-sectional | All 1392, Accepted 1078 | Low risk |
| [35] | Hailemariam SH, 2021        | 1th February to 1th March 2021 | southwest Ethiopia | During visit | Cross-sectional | All 412, Accepted 129 | Medium risk |
| [36] | Battarbee A.N, 2021         | August to December, 2020 | United States | During visit | Cross-sectional | All 915, Accepted 374 | Low risk |
| [37] | Hoque A.M, 2020             | September to October 2020 | Durban | During visit | Cross-sectional | All 346, Accepted 217 | Medium risk |
| [15] | Ceulemans M, 2021           | June and July 2020 | Belgium, Norway, Netherlands, Switzerland, Ireland and UK | Online survey    | Cross-sectional | All 6661, Accepted 3463 | Low risk |
| [16] | Gencer H, 2021              | July and October 2020 | Turkey | Online survey    | Cross-sectional | All 152, Accepted 80 | Medium risk |
| [1, 38] | Mappa I, 2021               | January to February 2021 | Italy | During visit | Cross-sectional | All 161, Accepted 136 | Medium risk |
| [1] | Geoghegan S, 2021           | January 2021     | Ireland     | During visit     | Cross-sectional | All 300, Accepted 114 | Medium risk |
| [39] | Nguyen LH, 2021             | January to February 2021 | Vietnam | Online survey    | Cross-sectional | All 651, Accepted 393 | Low risk |

NR: not reported, M: Month
* Time for duration of symptoms.

https://doi.org/10.1371/journal.pone.0272273.t001
Fig 2. Acceptance of COVID-19 vaccine in pregnant women (A) and sensitivity analysis (B).

https://doi.org/10.1371/journal.pone.0272273.g002
Fig 3. Subgroup analysis of acceptance of COVID-19 vaccine in pregnant women based on continent (A) and (B).

https://doi.org/10.1371/journal.pone.0272273.g003
vaccination was 72.48% (95% CI: 70.18–74.72). In addition, the relationship between COVID-19 vaccine acceptance in pregnant women with a history of influenza vaccination and no history of influenza vaccination showed (OR = 0.87 [95% CI: 0.71–1.06]; Heterogeneity: I² = 0, P = 0.574) (S1 Fig).

3.8. Meta-regression between vaccine acceptance variable and month of studies

Significant heterogeneity of vaccine acceptance for the month of the study was detected in meta-regression (P < 0.001) (Table 2).

3.9. Publication bias

Egger’s test has more power to detect publication bias and is close to one according to the results of Kendall correlation coefficient in Begg’s test and is not statistically significant (p = 0.82), and is also insignificant in Egger’s test (p = 0.888) and its confidence interval ranges from -8.67 to 7.58, and since it includes zero, it indicates that no publication bias has occurred (Fig 6).

4. Discussion

This study is the first systematic review and meta-analysis on COVID-19 vaccine acceptance in pregnant women worldwide. The total prevalence of COVID-19 vaccine acceptance in pregnant women was estimated at 53.4%, with the lowest and highest rates being 37% and 84.5%, respectively. To investigate the cause of heterogeneity between studies, subgroup analysis was performed based on continent, data collection method and meta-regression based on the month of the study, and only meta-regression was significant based on the month of the study. The effect of some variables such as gravid, maternal age and history of influenza vaccination on COVID-19 vaccine acceptance was evaluated, which was not significant. It was not possible to examine other causes, but it seems that the possible explanation for these differences may be differences in access to health care services and awareness about the severity of COVID-19.

Widespread vaccination is the most promising strategy to end this global pandemic. COVID-19 vaccination started in February 2021 and the World Health Organization has approved more than three COVID-19 vaccines to reduce the incidence and potential threat of the disease [40–43]. Nevertheless, it is believed that the resistance of people, especially pregnant women, is high despite rapid preparation of the vaccine [44–47] and researchers attribute it to the extraordinary advances in the development of effective and safe vaccines against COVID-19 in a short time [48, 49]. In a systematic review and meta-analysis, COVID-19 vaccine acceptance in the general population was over 70%, and gender, education level, history of influenza vaccination, and trust in government were strong predictors of COVID-19 vaccination [50] but our estimate in the general population was much lower. We also compared COVID-19 vaccine acceptance among pregnant women with previous infectious diseases such as the H1N1 flu pandemic; COVID-19 vaccine acceptance in this study was higher than H1N1 vaccine acceptance in 2009 (47%) among pregnant women in the United States [51]. Other systematic reviews on the acceptance of influenza and pertussis vaccines during pregnancy shows that concerns about vaccine safety are one of the most important factors influencing the decision to receive the recommended vaccines during pregnancy [19, 52–55]. Thus, resistance
to COVID-19 vaccine may be a limiting factor in global efforts to control the present pandemic, and have a negative impact on health and socio-economic aspects of society [55]. A previous systematic review also found that women were less likely to be vaccinated during the global influenza pandemic in 2009 [56]. This may be due to the fact that men show more risky behaviors than women [57]. Based on the Model of Health Belief, anticipated benefits (people who want to get the vaccine see a lot of anticipated benefits in receiving the COVID-19 vaccine to protect themselves and other people), cues to action (noteworthy predictors which elevated the intention to get COVID-19 vaccine were suggestions provided by the Ministry of Health and GP or conducting the vaccination at workplace), and anticipated severity (severity of disease shows that the people that want to receive the vaccine see themselves as a person who is at high risk of notable pain or experiencing side effects if they are infected with COVID-19, as compared to people that do not want to receive the vaccine) were the most important predictors of the intention to get COVID-19 vaccine [58, 59]. Another reason for resistance to vaccine is the widespread anti-vaccination campaign in cyberspace. Johnson et al. argue that the internet has increased the audience of the anti-vaccine movement, and that it is possible that the explosive growth of anti-vaccination perspectives will hinder the development and acceptance of vaccines [60].

In the present study, the effect of some variables such as gravida, maternal age and history of influenza vaccine on COVID-19 vaccine was not significant. The results of a systematic review and meta-analysis demonstrated that high income, gender, marital status, influenza vaccine in the previous season, fear of COVID-19, confidence in the health system, higher education, chronic illness, and perceived risk are effective factors in COVID-19 vaccine acceptance [61]. The COVID-19 pandemic had great effects not only on vaccination against this sickness but also on readiness to get other vaccines, for instance against influenza. As a matter of fact, a huge anxiety for the upcoming winter is the combination of COVID-19 and influenza. Previous research has shown how an influenza pandemic can raise the acceptance of vaccination for seasonal influenza [62].

This study showed that sociodemographic variables have an effect on the rate of COVID-19 vaccine acceptance in Botswana. The older people (55 and older) had the highest acceptance rate for vaccine and this may be related to the fact that people in this age group pay attention to news provided by government sources, while younger groups often use social media and internet, which is full of unverified information and also the fact that this population has a higher risk of developing a severe case of the disease. On the contrary, a study in China demonstrated that middle-aged people (30–49 years) were more willing to receive the vaccine compared to other age groups. As authors mentioned, factors that influence willingness to receive the vaccine included paying much attention to the latest news related to the vaccine, among other factors [63].

Moreover, according to a systematic review and meta-analysis by Kilich et al., which examined factors influencing vaccination decisions among pregnant women, these women believe

![Fig 5. COVID-19 vaccine acceptance among primigravid (A) and multigravida (B) pregnant women and the OR for COVID-19 vaccine acceptance primigravid and multigravida pregnant women (C).](https://doi.org/10.1371/journal.pone.0272273.g005)

Table 2. Meta-regression analysis of the effect of the factors on vaccine acceptance in pregnant women.

| Variable                        | Multivariable meta-regression |
|---------------------------------|-------------------------------|
| % vaccine acceptance in pregnant women | Coefficient | P-value | 95% conf. Interval |
| Publication month in 2021 years | 53.15            | <0.001  | (44.48–61.82)    |

![Table 2. Meta-regression analysis of the effect of the factors on vaccine acceptance in pregnant women.](https://doi.org/10.1371/journal.pone.0272273.t002)
that vaccination can cause birth defects, injuries, long-term effects and anxiety [46], and this has important implications for public health messages about COVID-19 vaccination during pregnancy [64].

The present study showed that vaccine acceptance among pregnant women has increased significantly over time, which may be due to communication strategies such as positive orientations for action, being encouraged by close and trusted people such as doctors and religious leaders, sharing personal experiences, and peer pressure [65]. It should also be noted that similar to the influenza vaccine, the definitive recommendation of obstetricians to pregnant women to inject the vaccine is likely to increase the acceptance of COVID-19 vaccine [66, 67]. On the other hand, other evidences indicate that doctors’ advice for vaccination is the most important factor in the mother’s decision, regardless of geographical or social background. Furthermore, during the pandemic, pregnant women’s anxiety about the health of the fetus and its health has a negative impact on their well-being. Numerous studies have also shown that health professionals, including midwives, can reduce the level of anxiety in pregnant women by supporting them [8, 19, 68].

Changes in acceptance levels among pregnant women during a pandemic disease may be influenced by socio-demographic factors such as age, gender, and income status, individual factors such as personal beliefs, political views, risk perception, and social or organizational factors such as social media [69]; many factors affecting COVID-19 vaccine acceptance, such
as geographical or socio-economic factors, hardly change and preliminary studies have not examined such variables.

Systematic strategies should be implemented to improve the acceptance of the COVID-19 vaccine among pregnant women. Previous research has shown that several combination interventions, including training sessions, easy access to vaccines, and vaccination rewards, can increase influenza vaccine acceptance [70]. We suggest that better health education and public health messaging can be used to address pregnant women’s concerns about fetal health and their own health. In addition, pregnant women should be informed about the benefits of protecting themselves, their family and friends after vaccination. We also recommend that national and individual interventions be performed to improve the COVID-19 vaccine acceptance among pregnant women in the future. At the national level, governments should instill public confidence in vaccines through scientific vaccine programs. In addition, governments need to be cautious and aware of potential anti-vaccine movements. In a part, it will be achieved by the integration of new emerging approaches and sciences to develop more reliable COVID-19 vaccine with minimum side effects in the future [71–74].

5. Limitations

One of the limitations of the present study is the lack of analysis in specific demographic subgroups due to the small number of articles.

6. Conclusion

The prevalence of COVID-19 vaccine acceptance in pregnant women was 53.46%, which was much lower than the general COVID-19 vaccination, but is consistent with the acceptance of other vaccines recommended in pregnancy such as influenza and tetanus, diphtheria and pertussis. Therefore, necessary interventions should be taken to increase the acceptance of the vaccine, address safety concerns and educate about it.

Supporting information

S1 Checklist. PRISMA 2009 checklist.

S1 Fig. COVID-19 vaccine acceptance among pregnant women with a history of influenza vaccination (A) without a history of influenza vaccination (B) and the OR for COVID-19 vaccine acceptance with a history of influenza vaccination and without a history of influenza vaccination pregnant women (C).

Acknowledgments

Thanks to guidance and advice from Clinical Research Development Unit of Baqiyatallah Hospital, Tehran, Iran. This manuscript was presented of the manuscript as preprint.

Author Contributions

Conceptualization: Milad Azami, Marzieh Parizad Nasirkandy, Reza Ranjbar.

Data curation: Milad Azami, Marzieh Parizad Nasirkandy, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar.

Formal analysis: Hadi Esmaeili Gouvarchin Ghaleh.
Investigation: Milad Azami.
Methodology: Milad Azami, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar.
Project administration: Reza Ranjbar.
Resources: Milad Azami.
Software: Milad Azami, Hadi Esmaeili Gouvarchin Ghaleh.
Supervision: Reza Ranjbar.
Validation: Milad Azami, Marzieh Parizad Nasirkandy, Reza Ranjbar.
Visualization: Milad Azami.
Writing – original draft: Milad Azami, Marzieh Parizad Nasirkandy, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar.
Writing – review & editing: Milad Azami, Marzieh Parizad Nasirkandy, Hadi Esmaeili Gouvarchin Ghaleh, Reza Ranjbar.

References
1. Geoghegan S, Stephens LC, Feemster KA, Drew RJ, Eogan M, Butler KM. “This choice does not just affect me.” Attitudes of pregnant women toward COVID-19 vaccines: a mixed-methods study. Human Vaccines & Immunotherapeutics. 2021;1–6. https://doi.org/10.1080/21645515.2021.1924018 PMID: 34009096
2. Diseases TLI. The intersection of COVID-19 and mental health. The Lancet Infectious Diseases. 2020; 20(11):1217. https://doi.org/10.1016/S1473-3099(20)30797-0 PMID: 33038942
3. Karimian M, Azami M. Chest computed tomography scan findings of coronavirus disease 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis. Polish Journal of Radiology. 2021; 86(1):31–49. https://doi.org/10.5114/prj.2021.103379 PMID: 33708271
4. Kotlar B, Gerson E, Petriklo S, Langer A, Tiemeier H. The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. Reproductive Health. 2021; 18(1):1–39.
5. Abdelazim IA, AbuFaza M, Al-Munafii S. COVID-19 positive woman presented with preterm labor: case report. Gynecology Obstetrics & Reproductive Medicine. 2021:1–3.
6. Organization WH. COVID-19 weekly epidemiological update, 19 January 2021. 2021.
7. Khoury R, Bernstein PS, Debolt C, Stone J, Sutton DM, Simpson LL, et al. Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at five New York City medical centers. Obstetrics & Gynecology. 2020; 136(2):273–282. https://doi.org/10.1097/AOG.0000000000004025 PMID: 32555034
8. Mortazavi F, Mehrabadi M, KiaeeTabar R. Pregnant women’s well-being and worry during the COVID-19 pandemic: a cross-sectional study. BMC pregnancy and childbirth. 2021; 21(1):1–11.
9. Pfizer B Pfizer and BioNTech Announce Vaccine Candidate against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. Pfizer. New York; 2020.
10. Moderna I. Moderna announces primary efficacy analysis in phase 3 COVE study for its COVID-19 vaccine candidate and filing today with US FDA for emergency use authorization. Moderna. 2020.
11. Pratama NR, Wafa IA, Budi DS, Putra M, Wardhana MP, Wungu CDK. Covid-19 Vaccination in Pregnancy: A Systematic Review. medRxiv. 2021.
12. COVID C Team R. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine—United States, December 21, 2020–January 10, 2021. Morbidity and Mortality Weekly Report. 2021; 70(4):125. https://doi.org/10.15585/mmwr.mm7004e1 PMID: 33507892
13. Burd J, Kino T, Segars J. The Israeli study of Pfizer BNT162b2 vaccine in pregnancy: considering maternal and neonatal benefits. The Journal of Clinical Investigation. 2021. https://doi.org/10.1172/JCI150790 PMID: 34101621
14. Bloom BR, Nowak GJ, Orenstein W. “When will we have a vaccine?”—Understanding questions and answers about Covid-19 vaccination. New England Journal of Medicine. 2020; 383(23):2202–4. https://doi.org/10.1056/NEJMmp2025331 PMID: 32897660
15. Caleumes M, Foulon V, Panchaud A, Winterfeld U, Pomar L, Lambelet V, et al. Vaccine willingness and impact of the COVID-19 pandemic on women’s perinatal experiences and practices—A
multinational, cross-sectional study covering the first wave of the pandemic. International journal of environmental research and public health. 2021; 18(7):3367. https://doi.org/10.3390/ijerph18073367 PMID: 33805097

16. Gencer H, Özkan S, Vardar O, Serçekuş P. The effects of the COVID 19 pandemic on vaccine decisions in pregnant women. Women and Birth. 2021. https://doi.org/10.1016/j.wombi.2021.05.003 PMID: 34088595

17. Perlis RH, Lazer D, Ognyanova K, Baum M, Santillana M, Druckman J, et al. The COVID States Project #9: Will Americans vaccinate themselves and their children against COVID-19. 2020.

18. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nature medicine. 2021; 27(2):225–8. https://doi.org/10.1038/s41591-020-1124-9 PMID: 33082575

19. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: a literature review. Vaccine. 2015; 33(47):6420–9. https://doi.org/10.1016/j.vaccine.2015.08.046 PMID: 26320417

20. Badfar G, Shohani M, Nasirkandy MP, Mansouri A, Abangah G, Rahmati S, et al. Epidemiology of hepatitis B in pregnant iranian women: a systematic review and meta-analysis. Archives of virology. 2018; 163(2):319–30. https://doi.org/10.1007/s00705-017-3551-6 PMID: 29063378

21. Azami M, Khataee M, Beigom Bigdeli Shamloo M, Abbasalizadeh F, Rahmati S, Abbasalizadeh S, et al. Prevalence and Risk factors of hepatitis B Infection in pregnant women of Iran: a systematic review and meta-analysis. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2016; 19(18):17–30.

22. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Systematic reviews. 2021; 10(1):1–19.

23. Moskalewicz A, Oremus M. No clear choice between Newcastle–Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer. Journal of clinical epidemiology. 2020; 120:94–103. https://doi.org/10.1016/j.jclinepi.2019.12.013 PMID: 31866469

24. Ades A, Lu G, Higgins J. The interpretation of random-effects meta-analysis in decision models. Medical Decision Making. 2005; 25(6):646–54. https://doi.org/10.1177/027298X05282643 PMID: 16282215

25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;1088–101. PMID: 7786990

26. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997; 315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563

27. Goncu Ayhan S, Oluklu D, Atalay A, Menekse Beser D, Tanacan A, Moraloglu Tekin O, et al. COVID-19 vaccine acceptance in pregnant women. International Journal of Gynecology & Obstetrics. 2021. https://doi.org/10.1002/ijgo.13713 PMID: 33872386

28. Sutton D D’Alton M, Zhang Y, Kahe K, Cepin A, Goffman D, et al. COVID-19 Vaccine Acceptance Among Pregnant, Breastfeeding and Non-pregnant Reproductive Aged Women. American journal of obstetrics & gynecology MFM. 2021: 100403.

29. Jayagobi PA, Ong C, Thai YK, Lim CC, Jiun SM, Koon KL, et al. Perceptions and acceptance of COVID-19 vaccine among pregnant and lactating women in Singapore: A cross-sectional study. medRxiv. 2021.

30. Levy AT, Singh S, Riley LE, Prabhu M. Acceptance of COVID-19 vaccination in pregnancy: A survey study. American journal of obstetrics & gynecology MFM. 2021. https://doi.org/10.1016/j.ajogmf.2021.100399 PMID: 34620098

31. Tao L, Wang R, Han N, Liu J, Yuan C, Deng L, et al. Acceptance of a COVID-19 vaccine and associated factors among pregnant women in China: a multi-center cross-sectional study based on health belief
model. Human Vaccines & Immunotherapeutics. 2021;1–10. https://doi.org/10.1080/21645515.2021.1892432 PMID: 33989109

35. Hailemariam S, Mekonnen B, Shifera N, Endalkachew B, Asnake M, Assefa A, et al. Predictors of pregnant women’s intention to vaccinate against coronavirus disease 2019: A facility-based cross-sectional study in southwest Ethiopia. SAGE open medicine. 2021; 9:20503121211038454. https://doi.org/10.1177/2050312121103845 PMID: 33989109

36. Battarbee A, Stockwell M, Varner M, Newes-Adey G, Daugherty M, Gyamfi-Bannerman C, et al. Attitudes toward COVID-19 illness and COVID-19 vaccination among pregnant women: a cross-sectional multicenter study during August-December 2020. medRxiv. 2021. https://doi.org/10.1055/s-0041-1735878 PMID: 34598291

37. Hoque A, Buckus S, Hoque M, Hoque G, Van Hal G. COVID-19 vaccine acceptability among pregnant women at a primary health care facility in Durban, South Africa. Eur J Med Health Sci. 2020; 2(5).

38. Mappa I, Luviso M, Distefano FA, Carbone L, Maruotti GM, Rizzo G. Women perception of SARS-CoV-2 vaccination during pregnancy and subsequent maternal anxiety: a prospective observational study. The Journal of Maternal-Fetal & Neonatal Medicine. 2021:1–4. https://doi.org/10.1080/14767058.2021.1910672 PMID: 33843419

39. Nguyen LH, Hoang MT, Nguyen LD, Ninh LT, Nguyen HTT, Nguyen AD, et al. Acceptance and willingness to pay for COVID-19 vaccines among pregnant women in Vietnam. Tropical Medicine & International Health. 2021; 26(10):1303–13. https://doi.org/10.1111/tmi.13666 PMID: 34370375

40. Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against coronaviruses: the state of the vaccines. Vaccines. 2020; 8(2):309. https://doi.org/10.3390/vaccines8020309 PMID: 32560340

41. Mesele M. Covid-19 vaccination acceptance and its associated factors in sodo town, wolaita zone, southern ethiopia: Cross-sectional study. Infection and Drug Resistance. 2021; 14:2361. https://doi.org/10.2147/IDR.S320771 PMID: 34194232

42. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. European journal of epidemiology. 2020; 35(4):325–30. https://doi.org/10.1007/s10654-020-00634-3 PMID: 32318915

43. Cooper S, Betsch C, Sambala EZ, Mchiza N, Wiysonge CS. Vaccine hesitancy—a potential threat to the achievement of vaccination programmes in Africa. Human vaccines & immunotherapeutics. 2018; 14 (10):2355–7.

44. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. Jama. 2016; 315 (11):1149–58. https://doi.org/10.1001/jama.2016.1353 PMID: 26978210

45. Benecke O, DeYoung SE. Anti-vaccine decision-making and measles resurgence in the United States. Global pediatric health. 2019; 6:2333794X19862949. https://doi.org/10.1177/2333794X19862949 PMID: 34194232

46. Ganguro SA, Galazka AM, Wolfe CR, Phillips LM, Miller E, Chen RT, et al. Impact of anti-vaccine movements on pertussis control: the untold story. The Lancet. 1998; 351(9099):356–61. https://doi.org/10.1016/s0140-6736(97)04334-1 PMID: 9652634

47. Wong L, Wong P, AbuBakar S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. Human vaccines & immunotherapeutics. 2020; 16(7):1511–20. https://doi.org/10.1080/21645515.2019.1706935 PMID: 31977285

48. Graham BS. Rapid COVID-19 vaccine development. Science. 2020; 368(6494):945–6. https://doi.org/10.1126/science.abb9923 PMID: 32385100

49. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. New England Journal of Medicine. 2020; 382(21):1969–73. https://doi.org/10.1056/NEJMhp2005630 PMID: 32227757

50. Wang Q, Yang L, Jin H, Lin L. Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors. Preventive Medicine. 2021;106694. https://doi.org/10.1016/j.ypmed.2021.106694 PMID: 34171345

51. Atalbawial I, Jamieson D, D’Angelo D, Singleton J, Santibanez T, Euler G, et al. Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women-10 states, 2009–10 influenza season. Morbidity and Mortality Weekly Report. 2010; 59(47):1541–5. PMID: 21124293

52. Sharma O, Sultan AA, Ding H, Triggie CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in immunology. 2020; 11:2413. https://doi.org/10.3389/fimmu.2020.585354 PMID: 33163000

53. Larson HJ, DeFigueiredo A, Xiaohong Z, Schulz WS, Verger P, Johnston IG, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016; 12:295–301. https://doi.org/10.1016/j.ebiom.2016.08.042 PMID: 27658738
54. Kilich E, Dada S, Francis MR, Tazare J, Chico RM, Paterson P, et al. Factors that influence vaccination decision-making among pregnant women: A systematic review and meta-analysis. PloS one. 2020; 15(7):e0234827. https://doi.org/10.1371/journal.pone.0234827 PMID: 32645112
55. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021; 9(2):160. https://doi.org/10.3390/vaccines9020160 PMID: 33669441
56. Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine. 2011; 29(38):6472–84. https://doi.org/10.1016/j.vaccine.2011.06.107 PMID: 21756960
57. Goldman RD, Yan TD, Seiler M, Cotanda CP, Brown JC, Klein EJ, et al. Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey. Vaccine. 2020; 38(48):7668–73. https://doi.org/10.1016/j.vaccine.2020.09.084 PMID: 33071002
58. Shmueli L. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health. 2021; 21(1):1–13.
59. Zampetakis LA, Melas C. The health belief model predicts vaccination intentions against COVID-19: A survey experiment approach. Applied Psychology: Health and Well-Being. 2021; 13(2):469–84. https://doi.org/10.1111/aphw.12262 PMID: 33634930
60. Johnson NF, Velásquez N, Restrepo NJ, Leahy R, Gabriel N, El Oud S, et al. The online competition between pro-and anti-vaccination views. Nature. 2020; 582(7811):230–3. https://doi.org/10.1038/s41586-020-2281-1 PMID: 32499650
61. Nindrea RD, Usman E, Katar Y, Sari NP. Acceptance of COVID-19 vaccination and correlated variables among global populations: A systematic review and meta-analysis. Clinical Epidemiology and Global Health. 2021: 100899. https://doi.org/10.1016/j.cejgh.2021.100899 PMID: 34771762
62. Rubin GJ, Potts H, Michie S. The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK. Health Technology Assessment. 2010; 14(34):183–266. https://doi.org/10.3310/hta14340-03 PMID: 20630124
63. Gan L, Chen Y, Hu P, Wu D, Zhu Y, Tan J, et al. Willingness to receive SARS-CoV-2 vaccination and associated factors among Chinese adults: a cross sectional survey. International journal of environmental research and public health. 2021; 18(4):1993. https://doi.org/10.3390/ijerph18041993 PMID: 33670821
64. Carbone L, Mappa I, Sirico A, Di Girolamo R, Saccone G, Di Mascio D, et al. Pregnant women’s perspectives on severe acute respiratory syndrome coronavirus 2 vaccine. American Journal of Obstetrics & Gynecology MFM. 2021; 3(4):100352. https://doi.org/10.1016/j.ajogmf.2021.100352 PMID: 33771762
65. Prematunge C, Corace K, McCarthy A, Nair RC, Pugsley R, Garber G. Factors influencing pandemic influenza vaccination of healthcare workers—a systematic review. Vaccine. 2012; 30(32):4733–43. https://doi.org/10.1016/j.vaccine.2012.05.018 PMID: 22643216
66. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020; 26:100495. https://doi.org/10.1016/j.eclinm.2020.100495 PMID: 32838242
67. Chervenak FA, McCullough LB, Brent RL. Professional responsibility and early childhood vaccination. The Journal of Pediatrics. 2016; 169:305–9. https://doi.org/10.1016/j.jpeds.2015.10.076 PMID: 26621045
68. Myers KL. Predictors of maternal vaccination in the United States: An integrative review of the literature. Vaccine. 2016; 34(34):3942–9. https://doi.org/10.1016/j.vaccine.2016.06.042 PMID: 27317458
69. Al-Jayyou si GF, Sherbaskan MAM, Ali LAM, El-Heneidy A, Alhussaini NWZ, Elhassan MEA, et al. Factors Influencing Public Attitudes towards COVID-19 Vaccination: A Scoping Review Informed by the Socio-Ecological Model. Vaccines. 2021; 9(6):548. https://doi.org/10.3390/vaccines9060548 PMID: 34073757
70. Rashid H, Yin JK, Ward K, King C, Seale H, Booy R. Assessing interventions to improve influenza vaccine uptake among health care workers. Health Affairs. 2016; 35(2):284–92. https://doi.org/10.1377/hlthaff.2015.1087 PMID: 26853832
71. Torabi R, Ranbar R, Halaji M, Heiat M. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review. Molecular and cellular probes. 2020; 53:101636. https://doi.org/10.1016/j.mcp.2020.101636 PMID: 32634550
72. Mohammadpour S, Torshizi Esfahani A, Halaji M, Lakh M, Ranbar R. An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19. Journal of Cellular Physiology. 2021; 236(1):49–54. https://doi.org/10.1002/jcp.29868 PMID: 32542735
73. Sheikhshahrokh A, Ranjbar R, Saeidi E, Dehkordi FS, Heiat M, Ghasemi-Dehkordi P, et al. Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): A review. Iranian Journal of Public Health. 2020; 49(Suppl 1):18. https://doi.org/10.18502/ijph.v49iS1.3666 PMID: 34268202

74. Mirzaei R, Karampoor S, Sholeh M, Moradi P, Ranjbar R, Ghasemi F. A contemporary review on pathogenesis and immunity of COVID-19 infection. Molecular biology reports. 2020; 47(7):5365–76. https://doi.org/10.1007/s11033-020-05621-1 PMID: 32601923